Normal view MARC view ISBD view

Calcified guinea worms in a South African Indian. [electronic resource]

By:

SELKON, J M

Contributor(s):

LATHAM, W J

Producer: 20030501Description: 918-9 p. digitalISSN:

0256-9574

Subject(s):

In: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde vol. 26

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.

Back to results

1141 Why diabetics are at risk in percutaneous coronary intervention and the appropriate management of diabetics in interventional cardiology.
by Reginelli, Joel P
1142 [Initial experience with the use of abciximab in the salvage treatment of acute coronary thrombosis in the Hemodynamics Laboratory].
by Rubboli, A
1143 Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
by Brener, S J
1144 Contemporary diagnosis and management of unstable angina.
by Reeder, G S
1145 Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition.
by Califf, R M
1146 Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin.
by Ferguson, J J
1147 Unexpected mortality reduction with abciximab for in-stent restenosis.
by Mukherjee, D
1148 Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
by Bertram, Ulf
1149 Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
by Steiner, Sabine
1150 Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
by Silva, M A
1151 Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation.
by Tornvall, P
1152 Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
by Gunasekara, Athula P
1153 Combined thrombolysis with abciximab favourably influences platelet-leukocyte interactions and platelet activation in acute myocardial infarction.
by Szabo, Sebastian
1154 Combination pharmacotherapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa inhibition.
by Bush, Howard S
1155 Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).
by Ashby, Dale T
1156 Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.
by Danzi, Gian B
1157 Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
by Brouse, Sara D
1158 Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
by Recio-Mayoral, A
1159 [The FINESSE trial].
by Petronio, Anna Sonia
1160 Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
by Estévez-Loureiro, Rodrigo